These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 34318442)

  • 1. A Review of Utility Measurement Methods Used in Pharmacoeconomic Submissions to HIRA in South Korea: Methodological Consistency and Areas for Improvement.
    Hong J; Bae EY
    Pharmacoeconomics; 2021 Oct; 39(10):1109-1121. PubMed ID: 34318442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines.
    Kennedy-Martin M; Slaap B; Herdman M; van Reenen M; Kennedy-Martin T; Greiner W; Busschbach J; Boye KS
    Eur J Health Econ; 2020 Nov; 21(8):1245-1257. PubMed ID: 32514643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Korean guidelines for pharmacoeconomic evaluation (second and updated version) : consensus and compromise.
    Bae S; Lee S; Bae EY; Jang S
    Pharmacoeconomics; 2013 Apr; 31(4):257-67. PubMed ID: 23322587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets.
    Law EH; Pickard AS; Xie F; Walton SM; Lee TA; Schwartz A
    Med Decis Making; 2018 Nov; 38(8):968-982. PubMed ID: 30403577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set.
    Ferreira PL; Antunes P; Ferreira LN; Pereira LN; Ramos-Goñi JM
    Qual Life Res; 2019 Dec; 28(12):3163-3175. PubMed ID: 31201730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Korean Guidelines for Pharmacoeconomic Evaluations: Updates in the Third Version.
    Bae EY; Hong J; Bae S; Hahn S; An H; Hwang EJ; Lee SM; Lee TJ
    Appl Health Econ Health Policy; 2022 Jul; 20(4):467-477. PubMed ID: 35275388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of QALY weights for QALY calculations: a review of industry submissions requesting listing on the Australian Pharmaceutical Benefits Scheme 2002-4.
    Scuffham PA; Whitty JA; Mitchell A; Viney R
    Pharmacoeconomics; 2008; 26(4):297-310. PubMed ID: 18370565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility values in National Institute for Health and Clinical Excellence (NICE) Technology Appraisals.
    Tosh JC; Longworth LJ; George E
    Value Health; 2011 Jan; 14(1):102-9. PubMed ID: 21211492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of pharmacoeconomic evaluations submitted for reimbursement in Korea.
    Yim EY; Lim SH; Oh MJ; Park HK; Gong JR; Park SE; Yi SY
    Value Health; 2012; 15(1 Suppl):S104-10. PubMed ID: 22265055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sourcing quality-of-life weights obtained from previous studies: theory and reality in Korea.
    Bae S; Bae EY; Lim SH
    Patient; 2014; 7(2):141-50. PubMed ID: 24578251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing and transforming PROMIS utility values to the EQ-5D.
    Hartman JD; Craig BM
    Qual Life Res; 2018 Mar; 27(3):725-733. PubMed ID: 29264776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mapping ALSFRS-R and ALSUI to EQ-5D in Patients with Motor Neuron Disease.
    Moore A; Young CA; Hughes DA
    Value Health; 2018 Nov; 21(11):1322-1329. PubMed ID: 30442280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation on the first 2 years of the positive list system in South Korea.
    Park SE; Lim SH; Choi HW; Lee SM; Kim DW; Yim EY; Kim KH; Yi SY
    Health Policy; 2012 Jan; 104(1):32-9. PubMed ID: 22001369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic literature review of health state utility values in head and neck cancer.
    Meregaglia M; Cairns J
    Health Qual Life Outcomes; 2017 Sep; 15(1):174. PubMed ID: 28865475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Utility Analysis Using EQ-5D-5L Data: Does How the Utilities Are Derived Matter?
    Yang F; Devlin N; Luo N
    Value Health; 2019 Jan; 22(1):45-49. PubMed ID: 30661633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review and critical appraisal of studies mapping from quality of life or clinical measures to EQ-5D: an online database and application of the MAPS statement.
    Dakin H; Abel L; Burns R; Yang Y
    Health Qual Life Outcomes; 2018 Feb; 16(1):31. PubMed ID: 29433510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mapping the FACT-B Instrument to EQ-5D-3L in Patients with Breast Cancer Using Adjusted Limited Dependent Variable Mixture Models versus Response Mapping.
    Gray LA; Wailoo AJ; Hernandez Alava M
    Value Health; 2018 Dec; 21(12):1399-1405. PubMed ID: 30502783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The estimation of health state utility values in rare diseases: do the approaches in submissions for NICE technology appraisals reflect the existing literature? A scoping review.
    Meregaglia M; Nicod E; Drummond M
    Eur J Health Econ; 2023 Sep; 24(7):1151-1216. PubMed ID: 36335234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measurement of utility.
    Thavorncharoensap M
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S43-9. PubMed ID: 24964698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.